Endometrial cancer: news from ASCO

Summary At ASCO 2022 important abstracts were presented. The programmed death1 (PD1) inhibitor dostarlimab was investigated in the phase III GARNET study advanced or metastatic endometrial cancer after failure of previous platinum-based combination chemotherapy. In first group patients with tumors dMMR (mismatch repair-deficiency) MSI‑H (microsatellite-high; A), median progression-free survival (PFS) significantly higher than pMMR repair-proficiency) those MSS (microsatellite-stable) (group B), i.e., 6.0 months A and 2.7 B. Overall > 50 17 months, respectively. Immunotherapy-related adverse events seen 23% patients, including grade 3 4 8% women. all, 9% discontinued treatment due to events. Another regimen is lenvatinib pembrolizumab. a randomized + pembrolizumab versus monotherapy doxorubicin paclitaxel second-line therapy cancer, chemotherapy-free superior. PFS2 all comer if they received pembrolizumab, compared receiving standard chemotherapy ( p < 0.0001). conclusion, checkpoint inhibitors ± are now established cancer. Overall, inclusion PD1 PDL1 systemic regimens offers significant opportunity for whose options past only included conventional chemotherapy, radiotherapy hormonal therapy.